Fujian Haixi Pharmaceuticals Co., Ltd. (Haixi Pharma, 02637) has announced that, effective 30 April 2026, all future corporate communications will be disseminated exclusively via electronic channels in accordance with Rule 2.07A of the Hong Kong Stock Exchange Listing Rules.

The company’s English and Chinese disclosures—including annual and interim reports, notices of meetings, circulars and other shareholder materials—will be accessible on both the corporate website (hxpharma.com) and the Hong Kong Stock Exchange’s platform (www.hkexnews.hk). Printed copies will be issued only upon specific request.

Non-registered shareholders will not receive postal notifications when new documents are uploaded. Instead, they are advised to monitor the two websites directly. Those wishing to revert to hard-copy materials can submit a completed request form to the Hong Kong share registrar, Tricor Investor Services Limited (17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong) or email 2637-ecom@vistra.com. The selected preference will remain valid until revoked.

Enquiries can be directed to Tricor’s hotline at +852 2980 1333 (Monday–Friday, 09:00–18:00, Hong Kong time) or via email to 2637-ecom@vistra.com.

The initiative, authorized by Chairman and Executive Director Dr. Kang Xinshan on behalf of the board, aligns Haixi Pharma with the exchange’s electronic communication framework while offering shareholders optional access to printed documentation.